{
    "root": "38bdc7bd-c714-452e-910a-c4afa36ef1f8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Qulipta",
    "value": "20250321",
    "ingredients": [
        {
            "name": "ATOGEPANT",
            "code": "7CRV8RR151"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "VITAMIN E POLYETHYLENE GLYCOL SUCCINATE",
            "code": "O03S90U1F2"
        }
    ],
    "indications": "QULIPTA is indicated for the preventive treatment of migraine in adults.",
    "contraindications": "QULIPTA is taken orally with or without food. ( 2.1 ) For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily. ( 2.1 ) For chronic migraine, the recommended dosage is 60 mg taken once daily. ( 2.1 ) Severe Renal Impairment or End-Stage Renal Disease ( 2.2 , 8.6 ): Episodic migraine: 10 mg once daily. Chronic migraine: Avoid use.",
    "warningsAndPrecautions": "QULIPTA 10 mg is supplied as white to off-white, round biconvex tablets debossed with “A” and “10” on one side in the following packaging presentations:\n                        \n                           Bottle of 30, NDC: 0074-7095-30\n                        \n                        QULIPTA 30 mg is supplied as white to off-white, oval biconvex tablets debossed with “A30” on one side in the following packaging presentations:\n                        \n                           Bottle of 30, NDC: 0074-7096-30\n                        \n                        QULIPTA 60 mg is supplied as white to off-white, oval biconvex tablets debossed with “A60” on one side in the following packaging presentations:\n                        \n                           Bottle of 30, NDC: 0074-7094-30",
    "adverseReactions": "QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA. Reactions have included anaphylaxis and dyspnea [see Warnings and Precautions (\n                     \n                        5.1\n                     \n                     )]."
}